BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lui GC, Chan HL. An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. Hepatology 2020;71:444-55. [PMID: 31237366 DOI: 10.1002/hep.30833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Chen MB, Wang H, Zheng QH, Zheng XW, Fan JN, Ding YL, Niu JL. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A systematic review and meta-analysis. PLoS One 2019;14:e0224773. [PMID: 31751366 DOI: 10.1371/journal.pone.0224773] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
2 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, Lui RN, Chan HL, Mok TS, Wong GL. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med 2020;9:7052-61. [PMID: 32780516 DOI: 10.1002/cam4.3378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2021. [PMID: 34687121 DOI: 10.1111/hepr.13726] [Reference Citation Analysis]
5 Yip TC, Wong VW. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti‐viral therapy. Aliment Pharmacol Ther 2021;54:722-3. [DOI: 10.1111/apt.16498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yip TC, Lee HW, Wong VW, Wong GL, Tse YK, Lui GC, Ahn SH, Chan HL. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2020;35:1610-8. [PMID: 32032974 DOI: 10.1111/jgh.15007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yip TC, Wong GL. HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough. J Gastroenterol Hepatol 2020;35:1661-2. [PMID: 33043509 DOI: 10.1111/jgh.15249] [Reference Citation Analysis]
8 Wong GL, Hui VW, Tan Q, Xu J, Lee HW, Yip TC, Yang B, Tse Y, Yin C, Lyu F, Lai JC, Lui GC, Chan HL, Yuen P, Wong VW. Novel machine-learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100441] [Reference Citation Analysis]
9 Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DQ, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie Q, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Quek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, Yu ML, Yuen MF, Nguyen MH. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatol Int 2021. [PMID: 34822056 DOI: 10.1007/s12072-021-10271-x] [Reference Citation Analysis]
10 Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2021. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Reference Citation Analysis]
11 Chun HS, Park S, Lee M, Cho Y, Kim HS, Choe AR, Kim HY, Yoo K, Kim TH. Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:3424. [PMID: 34298640 DOI: 10.3390/cancers13143424] [Reference Citation Analysis]
12 Lai JC, Wong VW, Yip TC, Hui VW, Tse YK, Lee HW, Liang LY, Lui GC, Chan HL, Wong GL. Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. J Gastroenterol Hepatol 2021;36:3487-99. [PMID: 34404113 DOI: 10.1111/jgh.15664] [Reference Citation Analysis]
13 Zhang Y, Li Z, Luo Q, Xu W, Wang L, Zhu S, Peng L, Xie C. Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. Antiviral Therapy 2022;27:135965352210823. [DOI: 10.1177/13596535221082399] [Reference Citation Analysis]
14 Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, Toyoda H, Esquivel CO, Bonham CA, Nguyen MH, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022. [PMID: 35234371 DOI: 10.1002/hep4.1923] [Reference Citation Analysis]
15 Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol 2021;116:1264-73. [PMID: 34074829 DOI: 10.14309/ajg.0000000000001157] [Reference Citation Analysis]
16 Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00601-7. [PMID: 34089852 DOI: 10.1016/j.cgh.2021.05.062] [Reference Citation Analysis]
17 Ramos J, de Mendoza C, Soriano V. HTLV-1 infection and health outcomes. The Lancet Infectious Diseases 2020;20:407-8. [DOI: 10.1016/s1473-3099(20)30133-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yip TC, Chan RNC, Wong VW, Tse YK, Liang LY, Hui VW, Zhang X, Li GL, Chan HL, Wong GL. Association of metformin use on metabolic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis and renal impairment. Health Sci Rep 2021;4:e352. [PMID: 34401527 DOI: 10.1002/hsr2.352] [Reference Citation Analysis]
19 Lim YS, Seto WK, Kurosaki M, Fung S, Kao JH, Hou J, Gordon SC, Flaherty JF, Yee LJ, Zhao Y, Agarwal K, Lampertico P. Review: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther 2022. [PMID: 35178711 DOI: 10.1111/apt.16788] [Reference Citation Analysis]
20 Men VY, Emery CR, Lam T, Yip PSF. Suicidal/self-harm behaviors among cancer patients: a population-based competing risk analysis. Psychol Med . [DOI: 10.1017/s0033291720004250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Mak JWY, Yuen NTK, Yip TCF, Lam RHM, Lam BKH, Cheng CTY, Wong GLH, Chan FKL, Ng SC. No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. J Gastroenterol Hepatol 2022. [PMID: 35338526 DOI: 10.1111/jgh.15838] [Reference Citation Analysis]
22 Gu J, Yu G, Zhang X, Zhang S, Cai H, Ye C, Yang Y, Li D, Tong Z, Shen H, Chen H, Ding F, Lai X, Liu J, Xu M, Wu W. Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China. Virol J 2021;18:19. [PMID: 33441170 DOI: 10.1186/s12985-021-01491-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. Am J Gastroenterol. 2020;115:1429-1438. [PMID: 32483003 DOI: 10.14309/ajg.0000000000000651] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]